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ABSTRACT 
 
In the past decade, the discovery of active pharmaceutical substances with high therapeutic value 
but poor aqueous solubility has increased, thus making it challenging to formulate these 
compounds as oral dosage forms. The bioavailability of these drugs can be increased by 
formulating these drugs as an amorphous drug delivery system. Use of porous media like 
mesoporous silica has been investigated as a potential means to increase the solubility of poorly 
soluble drugs and to stabilize the amorphous drug delivery system. These materials have 
nanosized capillaries and the large surface area which enable the materials to accommodate high 
drug loading and promote the controlled and fast release. Therefore, mesoporous silica has been 
used as a carrier in the solid dispersion to form an amorphous solid dispersion (ASD). Mesoporous 
silica is also being used as an adsorbent in a conventional solid dispersion, which has many useful 
aspects. This review focuses on the use of mesoporous silica in ASD as potential means to 
increase the dissolution rate and to provide or increase the stability of the ASD. First, an overview 
of mesoporous silica and the classification is discussed. Subsequently, methods of drug 
incorporation, the stability of dispersion and, much more are discussed. 
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1. INTRODUCTION 
 
Combinatorial chemistry and high-throughput 
screening of drugs has led to the discovery of 
more and more poorly water soluble drugs [1-3]. 
These are target specific drugs with poor 
aqueous solubility, which present a challenge              
for effective drug delivery. Many strategies            
have been explored to overcome their low 
bioavailability because of poor solubility. 
Converting crystalline drugs into an amorphous 
form is one the most promising tool to overcome 
the problem of poor solubility, as compared to 
simple micronization of drugs [4] or salt formation 
[5], which has many practical limitations. The 
process of amorphization of the drug substance 
involves disruption of the ordered structure of a 
crystal which can be achieved by using a 
process like melt cast, hot melt technology and 
spray drying [6,7]. Hence, amorphous drug exists 
at a higher free energy state and has higher 
mobility as compared to their crystalline 
counterpart. The amorphous drug has enhanced 
thermodynamic properties which lead to higher 
apparent solubility and dissolution rate [8-10]. 
Due to high internal energy and enhanced 
molecular mobility of amorphous system, it has a 
tendency to crystallize during storage and 
dissolution [11-13]. In order to benefit from the 
amorphous drug and to reduce the conversion 
into crystalline form, efforts have been made to 
reduce the driving force of recrystallization by 
use of precipitation inhibitors [14,15]. The 
chemical potential of the drug in crystalline phase 
is equal to the chemical potential on the liquid 
phase at melting point (Tm) of the crystalline 
drug. However, the chemical potential of the 
amorphous drug is high, which can be lowered 
by the addition of polymer. The drug dispersed in 
an inert water soluble carrier like polymer at the 
solid stage is known as solid dispersion. It is 
used to improve solubility of amorphous solid 
dispersion. Hence, the concept of solid 
dispersion is gaining momentum. The concept of 
solid dispersion was introduced by Sekiguchi and 
Obi [16] and it has become the preferred and 
most successful method to enhance the drug 
dissolution and to stabilize the amorphous solid 
dispersion (ASD). To achieve stable ASD, a 
single phase system with drug molecules 
miscible with the polymer in a single phase 
forming a glass solution is desired [17-21]. The 
physical stability of ASD has been attributed to 
several factors. The addition of polymer to ASD 
will help to stabilize the system by reducing the 
mobility of the drug molecules and by increasing 
the glass transition temperature of the glass 
solutions as compared to pure amorphous drugs, 
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and kinetically act as crystallization inhibitors  
[22-24]. Some scientists have also proved that 
the drug-polymer interactions are important for 
stabilization of ASD [22,25,26]. 
 
Another approach to stabilizing an amorphous 
drug delivery system is to use porous media or 
adsorbents. Porous media refers to materials 
with large surface areas (e.g. greater than 500 
m2/g) and pore volumes (e.g. greater than 1 
cm3/g) [18]. The International Union of Pure and 
Applied Chemistry (IUPAC) classified the porous 
media is based on pore size; micropore, 
mesopore, and macropore. Micropore has a 
mean pore diameter less than 2 nm, mesopores 
have a pore diameter in between 2- 50 nm and 
macropore have a pore diameter greater than 50 
nm.  
 
In the context of Noyes-Whitney equation [27], 
an enhancement of dissolution rate can be 
achieved by an increase in apparent solubility, 
reduced boundary-layer thickness and higher 
specific surface area [12,28]. Konno T and his 
co-workers demonstrated the use of porous 
media as a potential drug delivery system to 
improve solubility and dissolution rate [29-32]. 
The porous media may be advantageous in 
enhancing the physical stability of amorphous 
systems since it has a size constraint effect on 
the nucleation and crystal growth. According to 
the classical theory of homogeneous nucleation, 
crystal growth proceeds spontaneously once a 
critical nucleation size is reached. The system 
will exist in a non-crystalline state if nucleation 
and growth are prevented. This can be achieved 
if spatial constraints of a capillary are imposed 
[33]. Jackson and McKenna investigated the 
mechanism of vitrification using porous 
adsorbents with controlled pore glasses (CPG) 
with mean pore diameters ranging from 4 to 73 
nm and crystalline o-terphenyl as a model 
system [34]. Crystallization of o-terphenyl is not 
seen in CPG with 4nm pores, regardless of 
whether the pores are overfilled or underfilled. 
Since the critical nucleation size is 6.2 nm which 
is greater than the pore diameter of 4 nm i.e. 
there were not enough molecules in the pores to 
reach the critical nucleus and nucleation could 
not proceed. Hence, nanoconfinement of drugs 
prevents recrystallization of the drugs thereby 
stabilizing the amorphous system. It was found 
that the drug cannot re-crystallize when the 
space in which it is confined does not exceed the 
drug molecule width by at least a factor of 10 [35, 
36].This unique process can be utilized to deliver 
the poorly soluble drugs. 
The behavior of drug molecules confined to 
porous media is different than those in bulk. In 
the case of drug molecules confined to porous 
media, the drug molecules have an altered 
thermodynamic state which plays an important 
role in the physical stability and product 
performance. It may also influence the chemical 
stability as well. The purpose of this review is to 
focus on the use of mesoporous silica in 
amorphous oral drug delivery system. 
Mesoporous silica can be classified as ordered 
mesoporous silica and non-ordered mesoporous 
silica. 
 
2. ORDERED MESOPOROUS SILICA 
 
Ordered Mesoporous silica (OMS) are porous 
materials that exhibit an array of uniform 
mesopores. These have a pore diameter 
between 2 and 50 nm. OMS exhibit a very high 
specific surface area (up to 1500 m2/g) and pore 
volume (up to 1.5 cm3/g) and hence they have 
high porosity. OMS (MCM- Mobil Composition of 
Matter) were first synthesized by Mobil Oil 
Corporation in 1991. Since then, ordered 
mesoporous silica is attracting attention for 
applications in fields such as lasers, sensors, 
catalysis and solar cells [37,38]. Due to the 
unique features of silica based ordered 
mesoporous materials, they are excellent 
candidates for controlled drug delivery systems 
[39]: 
 
• These materials have ordered pore 
network, which is homogeneous in size 
and allow control of the drug loading and 
release kinetics for the drug 
• It has a high pore volume which can fit in 
large amount of pharmaceuticals 
• It has silanol containing surface that can 
be functionalized to allow better control 
over drug loading and release. 
 
Vallet-Regi research team proposed the use of 
ordered mesoporous silica as a drug delivery 
system on model drug Ibuprofen [38]. The pore 
channel of MCM-41 was loaded with ibuprofen 
and this system release the drug in a sustained 
manner. Since then, there has been a 
tremendous increase in the use of the 
mesoporous system as a drug delivery system. A 
significant growth and many efforts have been 
devoted to tailoring the nanostructure and 
textural properties which allow control over drug 
loading and release kinetics. To confine the large 
size molecule such as protein, Vallet-Regi 
developed a method for tailoring pore sizes of 
Santa Barbara series (SBA-15) mesoporous 
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material. They have used hydrothermal treatment 
to enlarge the pore diameters. The mesoporous 
material synthesized using this novel method 
were named SBA-15-3d, SBA-15-5d, and SBA-
15-7d, the number 3d, 5d and 7d stand for the 
total time of hydrothermal treatment in the 
autoclave [40]. The increasing pore size 
increased the drug loading and protein 
adsorption. 
 
Various studies have demonstrated enhanced in 
vitro dissolution properties of silica based 
materials for a wide variety of compounds. The 
mesoporous silicates improve the drug 
absorption by creating supersaturation in vivo 
[41]. In the context of Fick’s first law [42], 
increased intraluminal concentration may 
enhance the flux of drug across the 
gastrointestinal membrane and which eventually 
increases absorption. However, for optimal in 
vivo performance simply releasing the drug in a 
supersaturated state may not be sufficient, since 
rapid precipitation of drugs to more stable 
crystalline form may jeopardize the absorption 
[43-47]. If we maintain the supersaturated state 
for a sufficient period, it will result in increased 
absorption which in turn increases bioavailability. 
The addition of excipients which prevent and 
retard precipitation will be beneficial. This type of 
approach, i.e. in which the formulation 
components generate a supersaturated state of 
drug (Spring) and formulation component which 
stabilize the supersaturated solution, 
precipitation inhibitors (parachute) is known as 
Spring and Parachute approach [43,48]. Various 
dissolution enhancing technologies that are 
associated with the creation of supersaturation 
have been shown to benefit from incorporation of 
precipitation inhibitors, for e.g. solid dispersion 
[49,50], lipid base systems [44-47] or use of high 
solubility salts [43]. Speybroeck et al has 
demonstrated that the approach of combining 
SBA-15 with an appropriate precipitation inhibitor 
is established as a valuable tool to enhance the 
absorption of poorly soluble weak base 
itraconazole (ITZ) [51]. The pharmaceutical 
performances of two precipitation inhibitors 
(hydroxypropyl methyl cellulose (HPMC) and 
hydroxypropyl methyl cellulose acetate succinate 
(HPMCAS)) were studied. It was found that the 
addition of HPMC polymer proved to be a good 
stabilizer for ITZ supersaturation in intestinal 
media and the addition of HPMC to SBA-15 
resulted in more than 60% increase in absorption 
[51]. Ambrogi et al investigated the effect of 
ordered mesoporous silica like MCM-41 and  
SBA-15 [52,53] on carbamazepine. The 
dispersion prepared was amorphous in nature 
and showed improved dissolution and physical 
stability of the drug. 
 
2.1 Preparation of Ordered Mesoporous 
Silica 
 
The first ordered mesoporous silica synthesis is 
based on the use of a surfactant as structure 
directing agent for the silica [54,55]. At critical 
micelle concentration (CMC) in aqueous solution, 
surfactant molecules start to form aggregates, 
which are known as micelles. The shape and 
size of the micelle depend on several factors, 
such as chemical composition, auxiliary 
chemicals, nature of surfactant and reaction 
conditions such as concentration, pH and 
temperature. These micelles aggregate to form 
supramicellar structures which, depending on the 
conditions, can be cubic, hexagonal or lamellar 
to determine the final mesopores framework. The 
mechanism of formation of this material takes 
place by means of “liquid-crystal templating” (or 
cooperative self-assembly), in which the silicate 
material forms inorganic walls between ordered 
surfactant micelles, forming a template 
framework. The surfactant is removed by solvent 
extraction or calcination process at high 
temperature, this is the last stage of the process. 
As a consequence of template synthesis, a 
material with narrow pore size distribution and 
ordered distribution of mesopores are achieved. 
A range of new materials with an ordered 
distribution of mesopores, narrow pore size 
distribution, homogeneous pore morphology 
(hexagonal and cubic pores), high surface area 
(1000m2/g), tuneable pore size (2-10 nm) and 
high pore volume (1 cm3/g) has been 
synthesized. The pore diameter can be varied 
from 2 to 10 nm by the addition of auxiliary 
hydrocarbons such as alkylated benzene or by 
changing the alkyl chain length [40]. There are 
several types of mesoporous materials 
discovered, depending on the synthesis 
procedure for e.g. SBA series [56-58], MCM 
series [55,59-63], KIT-1 (Korea advanced 
institute of Science and Technology no. 1) [64], 
MSU series (Michigan State University) [65],and 
FSM-16 (Folded Sheet Material no.16) [66,67]. 
Fig. 1 shows the TEM image of most popular 
SBA-15 [68]. 
 
2.2 Stability of Drug Loaded on Ordered 
Mesoporous Silica 
 
The stability of ITZ formulation based on ordered 
mesoporous silica SBA-15 has been studied by 
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R. Mellaerts, et al. [69]. Upon contact with the 
simulated gastric fluid, ITZ is readily liberated 
from the pore space of SBA-15 carrier material; a 
supersaturated ITZ solution is obtained. When 
this dispersion was stored at 0% RH, the 
performance of the ITZ is maintained. 
Interestingly, at higher humidity condition of 52% 
and 97% RH, an even higher supersaturation 
level is obtained when the aged formulation is 
suspended in simulated gastric fluid. This is a 
very intriguing feature of this formulation. 
Conversely, solid dispersion made using polymer 
like PVP and HPMC, a decrease release 
performance on storage is observed due to 
crystallization of the drug on storage. Mellaerts R 
demonstrated that under humid conditions, SBA-
15 undergoes hydroxylation, which concentrates 
the SBA-15 surface more hydrophilic, which 
facilitates the liberation of poorly water soluble 
ITZ molecules upon competitive adsorption of 
water molecules in simulated gastric fluid as 
shown in Fig. 2 [69]. Thus, it is possible to tune 
the release profile of poorly water soluble drugs 
by varying SBA-15 hydrophilicity. It is 
hypothesized that at high drug loading of ITZ, the 
walls of SBA-15 are coated with drug molecules 
and thus there are structural changes that occur 
upon its storage at the humid condition, 
specifically the void space of SBA-15 are 
suppressed and thus the aggregation of 
hydrophobic ITZ is prevented [69]. Limnell et al 
[70] studied the stability of high drug load 
indomethacin formulations based on ordered 
mesoporous silica, MCM-41, and SBA-15 
materials. After drug loading, only a small 
amount of crystalline materials (<3.0 wt.-%) were 
detected by DSC. The physicochemical stability 
of the high drug load indomethacin formulation 
was found to be variable during prolonged 
storage under stressed conditions. Even though 
the physical stability of the samples was found 
satisfactory and drug release performance was 
rapid after storage. The dissolution studies 
revealed the ability of both MCM-41 and SBA-15 
microparticle to improve the dissolution of 
indomethacin by stabilizing it in a disordered 
state inside the mesopores and by further 
maintaining this state even during storage in 
accelerated conditions [71].  The chemical 
analyses show a decrease in the loading degree 
and possible indomethacin degradation product 
formation, especially in MCM-41 based samples 
after stressing. The indomethacin SBA-15 
formulation is more stable under stress condition, 
this result is in agreement with the study 
conducted by Van Speybroeck, et al. [72]. Ten 
(10) physicochemically diverse model 
compounds were successfully loaded onto SBA-
15. In all cases, the adsorbed drug fraction was 
found to be amorphous, as evidenced by DSC 
results. Amorphization of the compounds 
resulted in a significant improvement in the 
dissolution rate as compared to the crystalline 
drugs. On the storage of formulation at 25°C and 
52% RH, no drug crystallization was observed 
after 6 months and the pharmaceutical 
performance of the SBA-15 formulation was 
retained accordingly. The authors concluded that 
this established the potential of SBA-15 to yield 
physically stable, dissolution enhancing 
formulation, irrespective of a drug’s 
physicochemical profile. 
 
3. NON-ORDERED MESOPOROUS SILICA 
 
Various non-ordered mesoporous silica like 
Syloid, Sylysia and aeroperl have been used to 
improve the dissolution properties of poorly 
soluble drugs. This mesoporous silica has 
advantages over non-porous high surface area
 
 
 
Fig. 1. TEM images of mesoporous silica SBA-15; Reprinted from reference [68] with 
permission from ACS publications 
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Fig. 2. Effect of humidity on Ibuprofen loaded SBA-15 surfaces; reprinted from reference [69] 
with permission from Elsevier 
 
materials, in which the deposited molecules not 
just are adsorbed on the surface, but also 
confined to pore that are only a few molecular 
diameters wide hence preventing recrystallization 
[73-75]. Takeguchi and coworkers have 
evaluated the solid dispersion prepared using 
porous silica-sylysia 350 like nonporous Aerosil 
200 on model drug indomethacin [76]. The 
dissolution rate of indomethacin was faster in the 
solid dispersion prepared using sylysia as 
compared to solid dispersion prepared using 
aerosil. A similar study was conducted with 
model drug tolbutamide [77], bicalutamide [78], 
resveratrol [79] and the results were in 
agreement with the previous study conducted.  
 
3.1 Use of non-ordered Mesoporous 
Silica in Convention Solid Dispersion 
as Adsorbent 
 
Some scientists had used a combination of melt 
granulation and surface adsorption techniques to 
enhance the dissolution and tableting properties 
of poorly soluble drugs like Glibenclamide [80], 
Cefuroxime [81]. The solid dispersion of 
Cefuroxime used gelucire as melt dispersion 
carrier and Sylysia 350 as an adsorbent.  The 
surface adsorbent, Sylysia 350 was used not 
only to impart good flow and compressibility to 
dispersion granules but also to improve the 
dissolution rate by increasing the effective 
surface area [81]. Another study was conducted 
using poorly soluble drug sulfathiazole and 
polyvinyl pyrrolidone as a carrier and Syloid 
244FP as an adsorbent [82]. This method 
combined the advantages of conventional solid 
dispersion and surface solid dispersion by 
utilizing the adsorptive nature of porous silica 
particle and modifying the model drug into 
optimal molecular form [82]. This technology 
helps to prevent the recrystallization of the drug 
on storage by forming strong hydrogen bonds 
between the drug and polymer complex, which is 
adsorbed on the porous carrier with further 
stabilization effects of silanol group present on 
the pore surfaces. Due to the large surface area 
of this system, the dispersion is immediately 
dispersed as soon as it touches the dissolution 
media and prevents the crystal growth during 
dissolution and the higher dissolution rate was 
achieved [82]. 
 
3.2 Stability of Drug Loaded on Non-
ordered Mesoporous Silica 
 
Miura et al investigated the stability of poorly 
soluble drug K-832 using porous silica Sylysia 
740 (2.5 nm diameter pores and Sylysia 350   
(21 nm diameter pore) [83]. These formulations 
were stored in 60°C and 80% RH in open and 
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closed condition. It was observed that 
formulation stored in 60°C and 80% RH closed 
condition was difficult to crystallize amorphous K-
832 in the mesopores of the silica. However, the 
formulation stored in 60°C and 80% RH in open 
conditions showed a diffraction peak at low 
intensities in powder X-Ray diffraction analysis. 
DSC measurements revealed the difference in 
heat of fusion of K-832-Sylysia 740 formulation 
increases on storage; however, it is smaller than 
that of K-832-Sylysia 350 formulation. This result 
suggests that K-832 adsorbed on Sylysia 740, 
which has a smaller pore diameter, has a higher 
physical stability of amorphous K-832. 
Furthermore, molecular mobility was measured 
in relaxation time study using solid state 13C 
NMR, revealed that the molecular mobility of K-
832 was lower for the 2.5 nm pore than for the 21 
nm pores, thus making the crystallization rate of 
amorphous K-832 in the 2.5 nm pores much 
slower. The result is in agreement with the study 
conducted by Aso, et al. and Masuda, et al. 
[84,85]. They have correlated crystallization 
behavior of amorphous compounds with the 
difference in the molecular mobility of amorphous 
compounds, which were based on spin-lattice 
relaxation time measured by solid state 13C NMR 
spectroscopy based on Adams-Gibbs-Veogel 
equation.  
 
4. METHOD OF DRUG INCORPORATION 
ON MESOPOROUS SILICA 
 
Various methods are available for incorporation 
of drugs into mesoporous materials like solvent 
deposition methods [86-90], mechanical 
activation [70,91,92], vapor-phase mediated 
mass transfer [32, 93]. In spite, of the preparation 
method, mesoporous silica systems has high 
surface area and high surface energy, and 
adsorption of the drug molecules on the porous 
material allows the system as a whole to 
progress to a lower free energy state i.e. Gibbs 
free energy is reduced  and this type if systems 
are stable [18]. The drug exists as an amorphous 
material in these systems and crystallization of 
amorphous material will take place only if the 
thermodynamic state of the system is disturbed. 
In addition to thermodynamic factors, crystal 
growth and nucleation is hindered by spatial 
constraints, i.e. the pores are not able to 
incorporate enough molecules in order for them 
to reach a critical nucleation size [18,34,89]. 
 
The physical state of hydrophobic drug 
molecules in ordered mesoporous silica is 
influenced by the loading procedure. Mellaerts et 
al compared the drug incorporation methods 
using ordered mesoporous silica SBA-15 and 
model drugs ibuprofen and ITZ [94]. Three 
loading procedure were studied like adsorption 
from solution (solvent method), incipient wetness 
impregnation and heating of the drug and the 
SBA-15 physical mixture. ITZ was successfully 
dispersed in SBA-15 using adsorption from 
dichloromethane and incipient wetness 
impregnation method. ITZ molecules were 
molecularly deposited over micro- and 
mesopores at 20% drug loading. At the higher 
drug loading, an adsorbed layer is formed in 
which ITZ molecules interact in a way similar to 
glassy state. The solvent method favors the 
positioning of ITZ on mesopores wall and the 
incipient wetness impregnation methods favor 
positioning in the micropores. The sample 
prepared from solvent method shows fast 
release kinetics. Ibuprofen was successfully 
incorporated inside the micropores using melt 
method due to less viscosity in the molten state. 
Both ITZ and ibuprofen released fast from SBA -
15 when exposed to simulated gastric fluid and 
supersaturation solution are easily obtained. The 
loading of the ibuprofen and ITZ in ordered 
mesoporous silica by melt method depends on 
the drug molten viscosity, while the ability to form 
a homogeneous mixture of drug and silica prior 
to the melting step of the process depends on 
the density of the powders and method of 
blending. 
 
Some scientist has used supercritical fluid 
techniques (SCF) to load the drug in mesoporous 
silica since solvent immersion method often 
leads to the pores of mesoporous materials not 
be fully utilized, and results in a low drug loading 
efficiency and an increase in dissolution rate [95]. 
Li-hong and coworkers loaded ibuprofen onto 
MCM-41 using solvent immersion method and 
supercritical carbon dioxide drug loading 
procedure [95]. It was found that the amount and 
the depth of ibuprofen entered the pores of the 
mesoporous silica by SCF technique were larger 
than those by the solution immersion method. A 
similar study conducted on Vitamin E [96] and 
results were in agreement with the previous 
study. The drug loading methods like solvent 
immersion, supercritical carbon dioxide, and 
liquid carbon dioxide, were able to convert 
crystalline drug in the amorphous state [83,97-
99]. The spontaneous transition of crystalline to 
the amorphous state of drug occurred in physical 
mixes of drug and silica via a vapor phase-
mediated pathway for drugs with a relatively low 
vapor pressure [93]. This unique phase 
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transformation phenomena are a simple and 
effective way to improve the aqueous solubility 
and bioavailability of poor water soluble drugs. 
 
5. EFFECT OF SURFACE 
FUNCTIONALIZATION 
 
The drug loading is governed by interfacial 
interactions between the drug molecules and the 
surface of the mesoporous silica. The surface 
chemistry of the mesoporous silica determines 
the two common mechanisms like physical and 
chemical adsorption.  Generally, if one seeks 
enhanced drug dissolution, physical adsorption 
like hydrogen bonding, electrostatic and 
hydrophobic interactions are preferred. The 
unmodified mesoporous silica is covered by –OH 
groups, hence hydrogen bonding are the most 
common interaction [38,39]. Song et al. [100] 
studied the functionalized mesoporous silica 
SBA-15 with the amine group through post-
synthesis and one pot synthesis on model drug 
ibuprofen and bovine serum albumin. Fig 3 
represent the TEM images of surface 
functionalized mesoporous silica. It was found 
that the release rate of ibuprofen functionalized 
by post synthesis can be effectively controlled as 
compared to that from pure SBA-15 and SBA-15 
functionalized by one-pot synthesis due to ionic 
interaction between the carboxyl group in 
ibuprofen and an amine group on the surface of 
SBA-15. However, the release rate of bovine 
serum albumin functionalized by one-pot 
synthesis is more favorable due to the balance of 
electrostatic interaction and hydrophilic 
interaction between the bovine serum albumin 
and the functionalized SBA-15 matrix. Similar 
results were observed for mitoxantrone, the 
release rate is strongly dependent on the pH of 
the release medium and the type of surface 
functional group [101]. Conversely, Vallet-Regi 
and co-workers found that ibuprofen loading was 
higher in non-functionalized MCM-41 silica 
compared to amine-modified silica [102].            
A similar trend was observed for       
erythromycin [103].  
 
 
 
Fig. 3. TEM images of the different surface functionalized mesoporous silica, with their 
corresponding size distribution: (a and b) MSN45; (c) MSN90; (d) conventional MSN150;  
(e) MSN300; and (f) MSN500. The insets (in a, c, and d) are HRTEM images, reprinted from 
reference [104] with permission from Elsevier 
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6. EFFECT OF PORE SIZE AND 
PARTICLE SIZE  
 
The pore size can determine how large 
molecules can be loaded to the carrier molecule, 
and it is very crucial for drug loading because of 
the mesopores in mesoporous silica act as 
sieves. The pore should be accessible for drug 
molecule and in general, the pore diameter/drug 
molecule size should be >1. For high drug 
loading in the mesoporous material, the ratio of 
pore diameter/drug molecule size should be 
greater than 3. Shen et al. [90] studied the effect 
of pore size and particle size of ordered 
mesoporous silica material on model drug 
ibuprofen. Mesoporous silica material (MCM-41 
and SBA-15) with varied pore and particle size 
was co-spray dried at high drug loading with 
ibuprofen. The solid dispersion obtained has a 
significant enhancement in the dissolution rate, 
which was affected by physical state and particle 
size of ibuprofen in mesoporous structure. 
Amorphous state of ibuprofen was obtained 
when ibuprofen was co-spray dried with MCM-41 
and SBA-15 with a pore size smaller than 10 nm 
due to nano space confinement. In contrast, 
when ibuprofen is co-spray dried with SBA-15 
with a pore size of above 20 nm nanocrystal 
were obtained and it had a slower dissolution 
than SBA-15 and MCM-41. The particle size of 
mesoporous silica showed less than a 
pronounced effect on the dissolution of 
ibuprofen. Vallet-Regi [40] use the hydrothermal 
effect to make mesoporous silica with different 
pore size by use of different surfactant. The 
swelling effect of the surfactant template which 
ultimately leads to increase in pore size of SBA-
15 has increased from 8.4 mn up to 11.4 nm due 
to the increase in pressure. Control of the pore 
size and morphology of porous silica drug 
carriers have been found to affect the drug 
dissolution profile [105-107]. The release kinetics 
of confined drugs depends on pore diameter and 
the particle size/morphology, drug release may 
occur in the order of minutes, hours or even 
days. 
 
Horcajada et al. [108] also studied the effect of 
pore size of mesoporous silica MCM-41 on the 
drug loading on ibuprofen. MCM-41 was 
prepared with different pore sizes by using 
surfactant molecules with different lengths of the 
alkyl chain. Ibuprofen was adsorbed on 
mesopores of MCM-41 with varying pore size, 
more ibuprofen molecules were loaded into the 
carrier with the pore size of 3.6 nm (19% wt drug 
loading) than with a pore size of 2.5 nm (11% wt 
drug loading). Ibuprofen loaded on a carrier with 
3.6 nm pore size, a monolayer of drug molecules 
fully occupied the pore surface and the space in 
the middle of the pore was available to allow the 
drug molecules to freely diffuse as seen in Fig. 4. 
As the pore size decreased to 2.5 nm, due to 
geometrical consideration (steric hindrance) the 
close packing of the drug molecule along the 
pore wall was avoided. Zhang et al. [109] studied 
the another poorly soluble drug telmisartan on 
the spherical mesoporous silica, increasing pore 
size from 3.6 nm to 12.9 nm have increased the 
drug loading to 59.7% in 12.9 nm pores. Kinnari 
et al. [87] studied non-ordered mesoporous silica 
(Syloid AL-1 and 244) microparticle as a carrier 
for a hydrophobic drug ITZ. The drug loading 
was performed by the immersion method, in 
which the particles were immersed into 
concentration ITZ solution in dichloromethane 
(high and low drug concentration).  The two 
syloid showed similar drug loading capacities 
when low drug concentration was used despite 
their significant differences in the pore size, 
surface area, and pore volume. At high loading 
concentrations of ITZ, the loading capacities for 
syloid AL-1 and 244 was increased to 25.1 and 
32.8 w-% respectively. The higher drug loads 
observed for the mesoporous silica particles 
might be attributed to different pore geometry. 
The surface structure of the mesoporous silica 
contains a large amount of silanol groups that 
are favorable for interactions with ITZ through 
hydrogen bonds. ITZ was present in an 
amorphous form which resulted in a significant 
improvement in dissolution. The amorphous form 
of ITZ was confirmed by DSC, XPRD 
measurements, SEM. Further, the FTIR 
investigations revealed that loading process did 
not change the chemical structure or morphology 
of the particle surface. The release of ITZ at pH 
1.2 from Syloid AL-1 microparticle was found to 
be faster than Syloid 244 particles. 
 
7. EFFECT OF SOLVENT 
 
Drug loading is influenced by the polarity of the 
solvent. Dimethyl sulfoxide (DMSO) is very polar 
solvent and it can form competitive adsorption 
with the drug molecules causing a low degree of 
drug loading. Charnay et al. [110] systematically 
studied the effect of solvent (DMSO, 
dimethylformamide (DMF), dimethylacetamide 
(DMA), ethanol and hexane) on drug loading of 
poorly soluble drugs. It was revealed that 
ibuprofen was not loaded into the MCM-41 
mesoporous material when DMA is used as a 
solvent, this is the result of the extreme polarity 
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of the DMA solvent. However, in hexane, the 
loading capacity was up to 37% wt. The solvent 
plays an important role on the drug loading with 
mesoporous material based on TiO2 and Al2O3. 
 
8. DRUG RELEASE MECHANISM 
 
To design the optimal carrier system one must 
have a thorough understanding of drug release 
kinetics. The release profile of poorly soluble 
drugs can be fitted with Higuchi equation [111] 
(Eq. (1)).  
 
 = /                         (1) 
 
Where Q is the cumulative amount of drug 
release at time t, and K is the Higuchi constant. 
  
The release of drug molecules from the insoluble 
carrier is described by Higuchi equation. Since 
the mesoporous materials are manufactured 
using inorganic solvents and compound, they are 
not soluble in the aqueous solution under the 
biological condition and hence, as suggested by 
Higuchi equation the drug release from inorganic 
material is the diffusion controlled process [111]. 
Hence Higuchi equation can be applied to the 
carrier of the mesoporous system to explain the 
drug release kinetics [108,112,113]. Zhao et al 
[112] showed a pure Higuchi type of diffusion 
driven drug release with hollow magnetic 
mesoporous silica carrier on model drug 
ibuprofen. The results suggest the presence 
hydrogen bonding between the drug and 
mesoporous material. Hydrogen bonding is the 
weak intermolecular forces and hence it does not 
control the dissolution of the drug molecules from 
the mesoporous material.  However, Anderson et 
al [113] observed two-step release phenomenon 
with ordered mesoporous silica carrier according 
to the fitting of the release data with Higuchi 
equation due to the degradation of mesoporous 
carrier MCM-41 and SBA-3. Nevertheless, the 
deviation from Higuchi equation is less 
pronounced for the more stable mesoporous 
carrier. Similar two step release mechanism was 
observed for thermally stabilized PSi (TCPSi, 
thermally carbonized PSi and TOPSi, thermally 
oxidized PSi) and non-ordered mesoporous silica 
(Syloid AL-1 and 244) (Fig. 5) [87]. Kinnari et al 
showed that in the first stage, the physically 
entrapped drug molecule is released faster and 
in the second stage slower release rate is 
observed due to chemical bonding between the 
drug and the surface of the mesoporous 
materials which sufficiently agreed with the 
Higuchi model (Fig. 5). Some scientist showed 
that the drug molecule located on or near the 
surface of the porous material can be released 
quickly due to instant dissolution and release in 
medium, whereas the drug molecules packed 
deeper inside the pore network are released 
slower [72,114].  
 
 
 
Fig. 4. Ibuprofen molecules inside the pore channels of different pore sized MCM-4; reprinted 
from reference [108] with permission from Elsevier 
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Fig. 5. Release of itraconazole at pH 1.2 fitted with Higuchi model; reprinted from reference 
[87] with permission from Elsevier 
 
 
 
Fig. 6. Release profile of ibuprofen (initial 60%) at pH 5.5 fitted with Korsmeyer–Peppas model; 
Reprinted from reference [116] with permission from Elsevier 
 
The drug release kinetics from the mesoporous 
carrier can be described in a more 
comprehensive way by Korsmeyer –Peppas 
equation (Eq. ( 2)). 
 
 = 	

  = 

            (2) 
 
Where, F is the fraction of the drug release at 
time t, M is the total amount of loaded drug in the 
mesoporous carrier; Km is the kinetic constant 
and n is the release constant which describes the 
drug release mechanism [115]. 
If n= ½ in Eq. (2), this model is reduced to 
Higuchi model describes diffusion controlled 
release. The drug release characteristics of 
ibuprofen loaded TUD-1 and MCM-41 the 
release profile is fitted with the Korsmeyer-
Peppas model [116] is shown in Fig. 6. The 
kinetic constant of K=10.7 was observed for the 
TUD-1 carrier, which is higher than MCM-41 
(k=4.7) demonstrated the unrestricted release of 
the drug from release medium due to high 
accessibility and stability of the TUD-1-1 
mesoporous network. The modeling of the 
dissolution curve of the pure crystalline form of 
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ibuprofen shows the much slower release of the 
drug (k=0.6) compared to the mesoporous 
carrier. The release constant n revealed that the 
ibuprofen release mechanism of the TUD-
1(n=0.64) material was more diffusion based 
than the MCM-41 material (n=0.71). The highly 
accessible nano reservoir of the TUD-1 material 
provided a relatively unrestricted release of 
ibuprofen, whereas the long and narrow 
mesopores pathway of MCM-41 sterically 
hindered the free diffusion of ibuprofen from the 
mesopores. However, Korsmeyer-Peppas model 
was found to describe only the first 60% of the 
drug release [116,117]. 
 
The mesoporous silica carrier also affects the 
permeation properties of the drug molecules. The 
mesoporous silicon nanoparticle loaded with 
telmisartan significantly enhance telmisartan 
permeability and reduce the drug efflux        
[118]. The cellular uptake of mesoporous silica   
is highly time, concentration and size   
dependent.  
 
9. In vivo STUDIES 
 
The poor correlation between in vitro and in vivo 
results emphasizes the importance of animal 
tests when developing formulations with poorly 
soluble drugs. The poorly soluble drugs are 
successfully loaded into mesoporous silica as an 
amorphous or disordered form. The enhanced 
drug dissolution is observed when using 
mesoporous silica as a carrier. Hence we expect 
it to have enhanced bioavailability [40,48,97]. 
The in vivo performance of ordered mesoporous 
silica as a carrier for ITZ was evaluated in rabbits 
and dogs [40]. After oral administration of 
ordered mesoporous silica loaded with ITZ to 
dogs, the area under the curve 0-8 h (AUC0-8) 
was 681 ± 566 nM while no systemic ITZ was 
detected when pure crystalline ITZ was 
administered. In rabbits, after oral administration 
of ordered mesoporous silica loaded with ITZ, 
AUC0-24 was increased to 1069 ± 278 nM which 
was double of that of crystalline ITZ. When SBA-
15 is used as a mesoporous carrier, tmax was 
decreased to 4.2±1.8 h. The pharmacokinetic 
parameters obtained with SBA-15 were 
comparable to commercially available 
Sporanox®. Zhang et al. [109], studied the 
release and bioavailability of telmisartan loaded 
in the nano and microparticles of mesoporous 
silica, Fig. 7. Both nano and micro particle were 
compressed into tablets and the drug release 
rate was studied (MSN -nanoparticle tablet and, 
MSM-microparticle tablet). Fig. 7 shows the in 
vivo mean plasma concentration of telmisartan 
following an oral dose of a Micardis tablet and 
telmisartan loaded in the nano and microparticles 
of mesoporous silica in beagle dogs. The release 
rate is significantly improved in comparison with 
commercially available Micardis. The results 
were confirmed with subsequent in vivo studies 
in dogs. The AUC 0-72 h was approximately 1.29 
times greater when MSM was administered and 
the mean value of Cmax for MSN was 1,24 and 
1,13- fold greater than that of the commercially 
tablet and MSM. These results have shown that 
use of mesoporous material increases the 
bioavailability of the poorly water soluble BCS 
class II and IV drugs. The drug loaded in 
mesoporous silica create a supersaturated drug 
solution in vivo which has a tendency to 
crystallize out [41] and hence the addition of 
excipients which reduces precipitation will be 
useful. Some scientists have incorporated 
polymeric materials in amorphous formulations to 
inhibit the precipitation and in vivo studied were 
conducted in rats [48]. In this study, combined 
use of SBA-15 and precipitation inhibitor like 
HPMC and HPMCAS was used to improve oral 
absorption of ITZ. In vitro studies indicated that 
HPMC and HPMCAS inhibited the crystallization 
up to 4 hours. Surprisingly, in vivo studies carried 
out showed lower AUC of a formulation 
containing HPMCAS than formulation without 
HPMCAS. The formulation with HPMC showed 
the higher AUC than the formulation without 
HPMC. However, Vandecruys et al showed that 
precipitation kinetics cannot be effectively 
inhibited by excipients [119]. Further, the 
selection of excipients mediated precipitation 
inhibition is dealt on the empirical basis [43,119] 
and structure activity relationship is not yet 
established. It is well understood that degree of 
supersaturation and rate at which 
supersaturation is created affects the rate and 
mechanism by which precipitation occurs [120]. 
This phenomenon was studied on model drug 
fenofibrate in which ordered mesoporous      
silica SBA-15 and MCM-41 of varying             
pore diameters were loaded with fenofibrate.   
The in vitro release rate analysis showed         
that increase in release rate as we increase      
the pore size. However, the In vivo     
experiments conducted in rats showed the 
bioavailability of fenofibrate increases as we 
decrease the pore size [121]. More 
understanding is needed to gain a better 
understanding.  
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Fig. 7A. Release profile of telmisartan (TEL) from A) TEL-loaded MSN tablet, (B) TEL-loaded 
MSM tablet and (C) TEL commercial tablet in Phosphate buffer solution (pH6.8); Reprinted 
from reference [118] with permission from ACS publication; Fig. 7B: In vivo mean plasma 
concentration versus time curves of TEL following an oral dose of (a) a Micardis tablet,  
(b) a TEL-MSM tablet and (c) a TEL-MSN tablet (equivalent to 40 mg of TEL) in beagle dogs. 
Each data point represents the mean ± SD (n = 6); Reprinted from reference [118] with 
permission from ACS publication 
 
10. CONCLUSION 
 
Mesoporous silica is a promising candidate to 
improve the release profile of poorly soluble 
drugs. Since the drug loading is taking place by 
physical adsorption and subsequent pore filling a 
wide variety of drugs can be used and dosage 
forms can be prepared using a downstream 
process like compression or capsule filling. 
Although several in vitro studies showing the 
enhanced dissolution behavior by use of 
mesoporous silica are carried out, but there are 
relatively few in vivo studies on this topic. Hence, 
all the features of the mesoporous carrier have 
not been thoroughly explored. These 
mesoporous carriers not only improve the 
dissolution but also permeation of the drug 
across the gastrointestinal membrane. The data 
in the literature have demonstrated the scientific 
and commercial promises of using mesoporous 
silica as an amorphous delivery system.  
Amorphization of the drug loaded on the 
mesoporous materials occurs through the 
limitation of space i.e. if the pore size of the 
mesoporous material is smaller than the critical 
nucleation size which will eventually lead to 
stabilization of the amorphous drugs by 
decreasing mobility of the drug molecule by 
incorporating them in the pore of the mesoporous 
material. The system is physically stable due to a 
decrease in Gibbs free energy. However, more 
work is needed to understand the detailed 
mechanism of interactions of drugs in 
mesoporous silica. There is very little information 
available about the molecular arrangements and 
vibrational spectroscopy, which is used to gain 
information on molecular interactions such as 
hydrogen bonding and intermolecular forces and 
bonding between the drug molecule and the 
mesoporous material. Commercialization of 
mesoporous silica formulation is possible if the 
mechanism of interaction is studied in dept. Silica 
based material like aerosil have already been 
used as pharmaceutical excipients for several 
years and hence the obstacle for 
commercialization of the technology is minimal. 
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